Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 149, Issue 3, Pages 410-413Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2141.2010.08132.x
Keywords
thrombosis; asparaginase; acute leukaemia; paediatric
Categories
Funding
- MRC [MC_U137686856, G0300130] Funding Source: UKRI
- Great Ormond Street Hospital Childrens Charity [V0903] Funding Source: researchfish
- Medical Research Council [MC_U137686856, G0300130] Funding Source: researchfish
- Medical Research Council [G0300130, MC_U137686856] Funding Source: Medline
Ask authors/readers for more resources
P>We report the incidence and outcome of venous thrombosis (VT) in the UK acute lymphoblastic leukaemia (ALL) 2003 trial. VT occurred in 59/1824 (3 center dot 2%) patients recruited over 5 years with 90% occurring during a period of Asparagine depletion. Pegylated Escherichia Coli Asparaginase (Peg-ASP) 1000 units/m2 was used throughout. Thirty-four children received further Peg-ASP, most with concurrent heparin prophylaxis. There were no episodes of bleeding or recurrent thrombosis. Optimal Asparagine depletion is central to success of modern regimes for treatment of ALL. This report confirms a significant risk of thrombosis with such therapy, but demonstrates that re-exposure to Asparaginase is feasible and safe.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available